Clinic-led team of international researchers has now combined 77 of
these common genetic variants into a single risk factor that can be used
to improve the identification of women with an elevated risk of breast
cancer. This factor, known as a polygenic risk score, was built from the
genetic data of more than 67,000 women.
mechanisms get more worked out, the hope is that the HDAC compounds can
get on a more sound footing, but for now, they're minor players in the
oncology world. The second thought is whether Chipscreen plans to seek approval to market the drug anywhere outside China.
AbbVie agreed to buy Pharmacyclics--including its share of Imbruvica and
some pipeline meds--for $21 billion. The price stunned many analysts at
the time. "Most of our investments tend to be early-on, smaller, midsize," Gorsky told the Journal.
settlement, Novartis will pay Seattle-based Juno $12.25 million
immediately and add more payments down the road, including royalties if
the Swiss drug maker’s lead CAR-T product comes to market.
Paris-based biotech Cellectis has joined a handful of other companies in
going public with its chimeric antigen receptor (CAR) T-cell therapies,
grossing more than $228 million in its initial public offering (IPO) on
the Nasdaq last month.
Payers want to
know if they are getting value for their money. Darius Lakdawalla and
colleagues argue that care innovations should be valued by subtracting
the health benefits they yield from the cost of care. They use three
case studies—colorectal cancer and two treatments for multiple
myeloma—to illustrate that health benefits can be greater than, equal
to, or less than the cost of new treatments.
summarizes the French experience, where the French Haute Autorité de
Santé (HAS) has received legal mandates to steadily incorporate CE into
its CER activities. These experiences provide insights for other public
and private payers struggling with how and whether to follow a similar
there will never be a shortage of “wellness warriors” like Jess
Ainscough, Belle Gibson, and Candace Marie-Fox. When one dies or is
revealed as a fraud, others rise and the same people profit from them.
Same as it ever was, only far easier, thanks to the Internet.
the researcher in Italy who is under criminal investigation and has had
seven papers retracted, has lost yet another study. The latest
paper, in the European Journal of Cancer, studied mice with a genetic
alteration associated with lipomas (benign fatty growths) in humans.